Olmesartan Medoxomil/Amlodipine/Rosuvastatin Calcium/Ezetimibe

奥美沙坦酯/氨氯地平/瑞舒伐他汀钙/依折麦布

Report date: 2024/11/24 20:00:04

Base Information

Drug NameOlmesartan Medoxomil/Amlodipine/Rosuvastatin Calcium/Ezetimibe
Drug Alias NameDW-20181/DW-20182DWJ-1451DWJ1451
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsVoltage-gated calcium channel blockersHMG-CoA reductase inhibitors +[5] 
TargetsAngiotensin II Receptor Type 1Voltage-gated calcium channelHMG-CoA reductase +[4] 
Therapy Area/IndicationsDyslipidemiasHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsYes Olmesartan MedoxomilAmlodipineRosuvastatin Calcium
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDaewoong Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDaewoong Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsDyslipidemiasHypertension

Other Information

ATC CodeN/A
Related LinksN/A